<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=iso-8859-1"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle18
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link="#0563C1" vlink="#954F72"><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See below for a note & a link to a survey about metastatic prostate cancer.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Thx.<br>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Anne Breakey Hart [mailto:anne.breakeyhart@prostatecancer.ca] <br><b>Sent:</b> December 19, 2018 12:40 PM<br><b>To:</b> Anne Breakey Hart<br><b>Subject:</b> Important Survey - Zytiga PCODR Submission<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white;font-weight:normal'>Hello Everyone,<o:p></o:p></span></strong></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p> </o:p></span></strong></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white;font-weight:normal'>I want to let you know about an important submission to pCODR that is being led by the BC Cancer Agency. The Canadian Cancer Survivor Network (CSSN) and Prostate Cancer Canada (PCC) are working to together to complete the patient evidence submission. Below you will see more information. And please feel free to share with your groups.<o:p></o:p></span></strong></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p> </o:p></span></strong></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p> </o:p></span></strong></p><p class=MsoNormal><strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt;padding:0cm;background:white'>Abiraterone (Zytiga) SURVEY</span></strong><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black'><br><br><span style='background:white'>The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) and Prostate Cancer Canada (PCC) with insights and perspectives about living with and managing metastatic castration sensitive prostate cancer (mCSPC) from patients and caregivers in order to complete a patient evidence submission for a new indication for abiraterone (Zytiga)<strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm'>. </span></strong></span><br><br><strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm;background:white'>We are looking for input from patients with metastatic prostate cancer and their caregivers.</span></strong><span style='background:white'> The purpose of this survey is to understand the experience and/or the need for abiraterone (Zytiga) as a drug option for this cancer type. </span><br><br><span style='background:white'>The pan-Canadian Oncology Drug Review invites patient groups like CCSN and PCC to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.</span></span><o:p></o:p></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'>Please click on this link for the survey: </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.surveymonkey.com_r_Z9NPTHY&d=DwQFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=9heIRYwvZvK9YiTp6EmYB7x3ah4npZ0w1FDGBX0pzOw&m=Oq-azVnwE_YMUeA5la3HxGbWeYyhfV1ywdNSat5mOxs&s=YXTzFXpUC2MdO1VCrY3gVvKzx6qd_OzQsrtqF1_ZS4g&e=">https://www.surveymonkey.com/r/Z9NPTHY</a><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black'><br><br><span style='background:white'>The survey will remain open until<strong><span style='font-family:"Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm'> January 10th, 2019.</span></strong></span><br><br><span style='background:white'>Thank you very much for your participation and for sharing with your groups as you deem appropriate.<o:p></o:p></span></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:10.5pt;font-family:"Arial","sans-serif";color:black;background:white'>Anne<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Anne Breakey Hart, CVA<br></span></b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Manager, PCCN and Volunteer Engagement | Prostate Cancer Canada<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>Gestionnaire,</span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'> Mobilisation des bénévoles </span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>| Cancer de la Prostate Canada</span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></p><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>T </span></b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0070C0'>416-441-2131 ext./poste 229 | <b>E</b></span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'> </span><a href="mailto:anne.breakeyhart@prostatecancer.ca"><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:blue'>anne.breakeyhart@prostatecancer.ca</span></a><span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='color:#1F497D'><img border=0 width=200 height=74 id="Picture_x0020_1" src="cid:image001.png@01D49797.801F0740" alt="cid:image001.png@01D06C88.6A54F890"></span><span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'> <o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><a href="http://www.facebook.com/prostatecancercanada"><span style='color:blue;text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_2" src="cid:image002.png@01D49797.801F0740" alt=facebook></span></a><span style='color:#1F497D'> </span><a href="http://www.twitter.com/prostatecancerc"><span style='color:blue;text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_3" src="cid:image003.png@01D49797.801F0740" alt=twitter></span></a><span style='color:#1F497D'> </span><a href="youtube.com/prostatecancercanada"><span style='color:blue;text-decoration:none'><img border=0 width=24 height=24 id="Picture_x0020_4" src="cid:image004.png@01D49797.801F0740" alt=Youtube></span></a><span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><b><span style='color:#0067B1'>Win the ultimate sports car – The Acura NSX!</span></b><span style='color:#0067B1'> Order your raffle tickets now for a chance to win a supercar valued at more than $235,000! Call 1-855-441-1267 or visit </span><a href="https://www.rocktheroadraffle.ca/?&utm_source=e_tag&utm_medium=email&utm_campaign=rtr"><b><span style='color:blue'>rocktheroadraffle.ca</span></b></a><span style='color:#0067B1'>. Ontario residents only. LL #10397<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>